The cost of the inpatient management of febrile neutropenia in cancer patients - a micro-costing study in the Irish healthcare setting

Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

(2016) Michael E. Stokes et al.   JOURNAL OF MANAGED CARE PHARMACY

Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice

(2012) Derek Weycker et al.   BMC CANCER

CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?

(2012) Michael Drummond et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Costs Associated with Febrile Neutropenia in the US

(2012) Shannon L. Michels et al.   PHARMACOECONOMICS

Management of febrile neutropenia: ESMO Clinical Practice Guidelines

(2010) J. de Naurois et al.   ANNALS OF ONCOLOGY

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

(2010) Matti Aapro et al.   SUPPORTIVE CARE IN CANCER

Management of chemotherapy-associated febrile neutropenia

(2009) D Cameron   BRITISH JOURNAL OF CANCER

Evaluation of direct medical costs of hospitalization for febrile neutropenia

(2009) Nina Lathia et al.   CANCER

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

(2009) José Ignacio Mayordomo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Outcomes and Cost of Outpatient or Inpatient Management of 712 Patients With Febrile Neutropenia

(2008) Linda S. Elting et al.   JOURNAL OF CLINICAL ONCOLOGY